

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer

Annelieke A. Lemij^{a,b}, Nienke A. de Glas^a, Marloes G.M. Derks^a, Esther Bastiaannet^a, Jos W.S. Merkus^c, Titia E. Lans^d, Carmen C. van der Pol^e, Thijs van Dalen^f, Annelie J.E. Vulink^g, Leander van Gerven^h, Onno R. Guicheritⁱ, Eugenie M.H. Linthorst-Niers^j, Frederiek van den Bos^k, Judith R. Kroep^a, Gerrit-Jan Liefers^b, Johanneke E.A. Portielje^a

^aDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands

^bDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands

^cDepartment of Surgery, Haga Hospital, The Hague, The Netherlands

^dDepartment of Surgery, Admiraal de Ruyter Hospital, Goes, The Netherlands

^eDepartment of Surgery, Alrijne Hospital, Leiden and Leiderdorp, The Netherlands

^fDepartment of Surgery, Diaconessenhuis, Utrecht, The Netherlands

^gDepartment of Medical Oncology, Reinier de Graaf Gasthuis, Delft, The Netherlands

^hDepartment of Internal Medicine, Langeland Hospital, Zoetermeer, The Netherlands

ⁱDepartment of Surgery, Haaglanden Medical Center, The Hague, The Netherlands

^jDepartment of Surgery, Groene Hart Hospital, Gouda, The Netherlands

^kDepartment of Gerontology & Geriatrics, Leiden University Medical Center, Leiden, The Netherlands

Corresponding author

G.J. Liefers

Leiden University Medical Center, department of Surgery

P.O. Box 9600

2300 RC Leiden


The Netherlands

+31 71 526 40 05


g.j.liefers@lumc.nl

Breast Cancer Research and Treatment

Supplemental figure A: Flowchart



Supplemental figure B: Other subscales from the EORTC QLQ30 and QLQ BR23 questionnaires




[#]A higher score indicates a worse outcome; ^{*}A higher score indicates a better outcome.

Adjusted for age, tumour stage, BMI, Charlson Comorbidity Index, polypharmacy, and type of surgery.

T1 – baseline, 3 months after diagnosis, start adjuvant endocrine therapy; T2 – 6 months after diagnosis; T3 – 12 months

Supplemental figure C: Other subscales from the EORTC QLQ30 and QLQ BR23 quality of life questionnaires



[#]A higher score indicates a worse outcome; *A higher score indicates a better outcome.

Adjusted for age, tumour stage, BMI, Charlson Comorbidity Index, polypharmacy, and type of surgery.

T1 – baseline, 3 months after diagnosis, start adjuvant endocrine therapy; T2 – 6 months after diagnosis; T3 – 12 months after diagnosis; T4 – 24 months after diagnosis